Cannabidiol for Reduction of Brain Neuroinflammation
Status:
Not yet recruiting
Trial end date:
2026-12-15
Target enrollment:
Participant gender:
Summary
We will study whether cannabidiol (CBD), the primary centrally and peripherally active
non-intoxicating compound in the cannabis plant, exerts anti-neuroinflammatory effects in
patients with chronic low back pain (cLBP) with or without mild-to-moderate depression.